2023-12-13 08:02:09 ET
- Shattuck Labs ( STTK ) +106% Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients.
- Innovative International Acquisition ( IOAC ) +35% .
- Applied UV ( AUVI ) +21% .
- QuantaSing Group ( QSG ) +17% Q1 earnings call release
- Mynaric ( MYNA ) +17% receives $33 million order from Northrop Grumman.
- C4 Therapeutics ( CCCC ) +15% .
- LifeMD ( LFMD ) +12% surges 17%, Medifast invests $20M.
- Aurora Mobile ( JG ) +11% climbs 7% subsidiary to provide email services to Rain Classroom
- Centogene ( CNTG ) +3% Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone
- Vertex Pharmaceuticals ( VRTX ) +7% gains as diabetic pain therapy succeeds in mid-stage trial.
- Singing Machine ( MICS ) +6% .
- Xponential Fitness ( XPOF ) +6% .
- Theratechnologies ( THTX ) +7% Announces FDA Approval of Trogarzo 90-Second Intravenous (IV) Push Loading Dose.
For further details see:
CCCC, XPOF and AUVI are among pre market gainers